ICH standards and guidelines for drug trials
Why is every single signatory to this agreement ignoring it?
According to the ICH - of which the FDA, the EMA amongst many others - says this about drug trails:
INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE (ICH) INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2)
https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
Section 1.1 states:
1.1 Adverse Drug Reaction (ADR) In the pre-approval clinical experience with a new medicinal product or its new usages, particularly as the therapeutic dose(s) may not be established: all noxious and unintended responses to a medicinal product related to any dose should be considered adverse drug reactions. The phrase responses to a medicinal product means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility, i.e., the relationship cannot be ruled out. Regarding marketed medicinal products: a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of diseases or for modification of physiological function (see the ICH Guideline for Clinical Safety Data Management: Definitions and Standards for Expedited Reporting).
So in other words - with experimental medicines err on the side of caution and assume the problem was caused by the drug unless or until proven otherwise.
So why is this being ignored by every single regulator and signatory to this agreement for the covid jabs?
Anything to do with the Bill and Melinda Gates Foundation being observers by any chance?